Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earnings

Set Alert for Sales & Earnings

Eastern European Results Roundup: Grindeks, Alkaloid, Olainfarm, Podravka, Sopharma

Several Eastern European generics companies achieved sales growth in 2018. Looking ahead, Grindeks plans to strengthen its presence in Russia and other CIS countries, Alkaloid is set to continue investing in production facilities and technologies, while Olainfarm looks to upgrade its product dossiers.

Europe Companies

Akorn Faces Hurdles In Returning To Path Of Profitable Growth

A new management team at Akorn is making progress on moving on from Fresenius Kabi’s ill-fated takeover bid; but putting manufacturing problems behind the US injectables and ophthalmics specialist is proving difficult.
Business Strategies Sales & Earnings

Perrigo Persists On Pepcid As Prescription Profit Plummets

Perrigo has won a US appeals court ruling on its generic version of Pepcid Complete. However, the company’s Prescription generics business saw a 15% drop in sales and a 28% decline in operating profit as the firm reported its 2018 results, ahead of plans to separate the Prescription unit from the company as it transitions to become a ‘self-care’ company.

United States Generic Drugs

Sluggish Copaxone Rival And Delay To Generic Advair Hurt Mylan

Mylan has blamed a sluggish uptake for its Copaxone rival and a delay in FDA approval of its generic version of Advair Diskus for the firm’s sales suffering a 4% drop and EBITDA falling by 8% in 2018.

Sales & Earnings Strategy

Mallinckrodt Sets Out Four Priorities For 2019 And Foresees Specialty Generics Growth

Completing the planned spin-off of its specialty generics and API business into an independent publicly-traded company is one of four priorities that Mallinckrodt has set out for 2019. Despite expecting a “relatively negative” pricing environment this year, chief executive Mark Trudeau believes the Specialty Generics division will achieve growth.

Business Strategies Generic Drugs

Endo Breaks Off Deal To Acquire Somerset And Wintac

Endo has announced that it will not pursue a previously-announced US$190 million deal to augment its injectables portfolio and pipeline by acquiring Somerset Therapeutics and its India-based Wintac contract development and manufacturing business. The news comes as Endo has reported US generics sales down by a third – and total turnover down by 15% – in 2018.

Deals Strategy
See All
UsernamePublicRestriction

Register